---
trial_id: 250
discovery_date: 2022-03-29 21:28:27.930810
date: 2022-03-29 21:28:27.930810
title: "A Multicenter, Open-Label, Immunogenicity and Safety Study of Avonex® (Interferon Beta-1a) 30 mcg Administered Subcutaneously to Subjects With Relapsing Multiple Sclerosis"
summary: |
  <p>EudraCT Number: 2008-003098-42<br />Sponsor Protocol Number: 108MS303<br />Sponsor Name: Biogen Idec Ltd<br />Start Date: 2009-01-06<br />Medical condition: To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing Multiple Sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003098-42/CZ">CZ</a> (Completed)</p>
link: 'https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2008-003098-42'
published_date: NaT
trial_source: Clinical Trials Register Europe
relevant: 
options:
  unlisted: false
---
<p>EudraCT Number: 2008-003098-42<br />Sponsor Protocol Number: 108MS303<br />Sponsor Name: Biogen Idec Ltd<br />Start Date: 2009-01-06<br />Medical condition: To evaluate the immunogenicity of Avonex® 30 mcg when administered SC to interferon-naïve subjects with relapsing Multiple Sclerosis<br />Disease: <br />Version: 9.1<br />SOC Term: <br />Classification Code: 10028245<br />Term: Multiple sclerosis<br />Level: LLT<br /><br />Population Age: Adults<br />Gender: Male, Female<br />Trial Protocol: <a href="https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-003098-42/CZ">CZ</a> (Completed)</p>